Triple-Negative Breast Cancer: An Analysis of Clinicopatho-logical Correlations an Treatment Approaches

Breast cancer is the most common malignant neoplasm in women, with the exception of non-melanoma skin cancers. Today, immunohistochemical assays can assess the presence of tumor biomarkers such as estrogen receptor, progesterone receptor, and epidermal growth factor receptor 2. Triple-negative breast cancer does not express any of these receptors and exhibits aggressive behavior, associated with a high risk of recurrence and metastasis. Currently, due to the absence of target biomarkers, nonspecific chemotherapy is the mainstay of treatment for this type of tumor. The lack of viable pharmacological targets for triple-negative tumors has prompted research demonstrating that triple-negative tumors exhibit molecular heterogeneity, a fact that may contribute to the development of more effective treatments in the future.